BioAge Labs has reported promising interim Phase 1 data for its oral NLRP3 inhibitor, BGE-102, which demonstrates significant reductions in inflammatory biomarkers associated with cardiovascular risk. CEO Kristen Fortney highlighted that BGE-102 achieved an impressive 86% median reduction in high-sensitivity C-reactive protein (hsCRP) among participants with obesity, positioning it as a potential oral alternative to injectable anti-inflammatory therapies. The company plans to initiate a Phase 2a proof-of-concept trial focused on cardiovascular risk in the first half of 2026, with full Phase 1 data expected soon.

This development is particularly relevant for the longevity field, as BGE-102’s profile not only targets cardiovascular diseases but is also being expanded into ophthalmology, specifically for diabetic macular edema (DME). The anticipated Phase 1b/2a trial for DME will run concurrently with the cardiovascular study, underscoring the therapeutic versatility of BGE-102.

The significant financial backing from a recent $132.3 million public offering will support BioAge’s ambitious clinical programs, highlighting the increasing investor interest in therapeutics that address aging-related inflammation and metabolic diseases.

Source: lifespan.io